STOCKHOLM, Jan. 20, 2020 /PRNewswire/ -- Medivir AB
(Nasdaq Stockholm: MVIR) announces that the phase II study
of MIV-711 in patients with osteoarthritis has been published in
the respected journal Annals of Internal Medicine (DOI:
10.7326/M19-0675). The title of the article is "Disease-Modifying
Effects of a Novel Cathepsin K Inhibitor in Osteoarthritis",
author; P.G Conaghan et al. In the same issue there is an editorial
by J.N Katz, MD, Msc, with the title; "Structural Modification in
Osteoarthritis: Dawn of a New Day", (DOI: 10.7326/M19-3809),
where the study results are discussed.
Dr. Katz mentions the significant effect on changes in bone and
cartilage degradation after six months of treatment with MIV-711,
the high quality of Medivir's study data, as well as the likely
need for longer treatment time to enable significant effect on
pain.
"We are pleased that our study with MIV-711 in osteoarthritis
has been published in a highly reputable scientific journal and
that an editorial in the same issue suggests that our study may
point to a way forward for disease modifying medicines for
osteoarthritis", said Dr Uli
Hacksell, CEO of Medivir. "We hope that this will increase
the external interest for MIV-711 as we continue to search for a
partner for the further development of MIV-711".
About osteoarthritis
Up to 40 percent of the population over 65 suffer from
osteoarthritis (OA), characterized by pain and varying degrees of
inflammation in one or more joints, mainly knees, hips and hands.
Osteoarthritis in weight-bearing joints, like knees and hips,
induces an increasing level of pain and decreased mobility for the
patient, and may eventually result in joint replacement surgery.
Drugs capable of slowing, stopping or even reversing the
progression of the disease are referred to as Disease Modifying
Osteoarthritis Drugs (DMOAD). There is currently no such therapy
approved for osteoarthritis and current treatments affect only day
to day symptoms without affecting degenerative changes in the
diseased joint.
About MIV-711
MIV-711 is a potent and selective inhibitor of cathepsin K, the
principal protease involved in breaking down collagen in bone and
cartilage. It is being developed to slow, stop or reverse the
progressive degeneration of joints affected by osteoarthritis, and
is therefore a potential DMOAD.
About Medivir
Medivir develops innovative drugs with a focus on cancer where the
unmet medical needs are high. The company is investing in
indication areas where available therapies are limited or missing
and there are great opportunities to offer significant improvements
to patients. Collaborations and partnerships are important parts of
Medivir's business model and the drug development is conducted
either by Medivir or in partnership. Medivir's share (ticker: MVIR)
is listed on Nasdaq Stockholm's Small Cap list.
www.medivir.com.
For further information, please contact:
Uli Hacksell
CEO
Medivir AB
Phone: +46(0)8-5468-3100
This information was brought to you by Cision
http://news.cision.com
https://news.cision.com/medivir/r/medivir-s-phase-ii-study-of-miv-711-in-patients-with-osteoarthritis-published-in-annals-of-internal-,c3011596
The following files are available for download:
|
https://mb.cision.com/Main/652/3011596/1176545.pdf
|
Press release
(PDF)
|
View original
content:http://www.prnewswire.com/news-releases/medivirs-phase-ii-study-of-miv-711-in-patients-with-osteoarthritis-published-in-annals-of-internal-medicine-300989475.html
SOURCE Medivir
